EnteroMedics, the developer of medical devices using neuroblocking therapy to treat obesity, metabolic diseases and other gastrointestinal disorders, announced the launch of vBloc Access, a program designed to support patient access to vBloc Neurometabolic Therapy.
vBloc Access is a comprehensive patient support program that provides individuals considering vBloc Neurometabolic Therapy with help in understanding their insurance benefits and the insurance claim process.
vBloc Access is available to physicians and healthcare providers as a resource for navigating the reimbursement process, including billing and coding assistance.
"EnteroMedics is pleased to offer patients and physicians with a resource to help them navigate the reimbursement process and provide expanded access to vBloc Neurometabolic Therapy," said Brad Hancock, EnteroMedics Chief Commercial Officer.
"vBloc Neurometabolic Therapy is a unique product that enables healthy weight loss through a better patient experience. With the vBloc Access program, we look forward to supporting physicians and patients in meeting the rapidly growing interest in and demand for vBloc Neurometabolic Therapy."
EnteroMedics is a medical device company focused on the development and commercialization of its neuroscience based technology to treat obesity and metabolic diseases.
vBloc Neurometabolic Therapy, delivered by a pacemaker-like device called the Maestro Rechargeable System, is designed to intermittently block the vagus nerves using high-frequency, low-energy, electrical impulses.
EnteroMedics’ Maestro Rechargeable System has received US Food and Drug Administration approval, CE Mark and is listed on the Australian Register of Therapeutic Goods.